Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials

Purpose To report the final analysis of survival outcomes for children with newly diagnosed high‐grade glioma (HGG) treated on the “Head Start” (HS) II and III protocols with chemotherapy and intent to avoid irradiation in children 6 years old or at the time of tumor progression. Results The 5‐year...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2016-10, Vol.63 (10), p.1806-1813
Main Authors: Espinoza, Juan C, Haley, Kelley, Patel, Neha, Dhall, Girish, Gardner, Sharon, Allen, Jeffrey, Torkildson, Joseph, Cornelius, Albert, Rassekh, Rod, Bedros, Antranik, Etzl, Morris, Garvin, James, Pradhan, Kamnesh, Corbett, Robin, Sullivan, Michael, McGowage, Geoffrey, Stein, Dagmar, Jasty, Rama, Sands, Stephen A., Ji, Lingyun, Sposto, Richard, Finlay, Jonathan L.
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Brain Neoplasms - drug therapy
Brain Neoplasms - mortality
Brain Neoplasms - radiotherapy
Child
Child, Preschool
Clinical Trials as Topic
Female
Glioma - drug therapy
Glioma - mortality
Glioma - radiotherapy
gliomas
Head Start
Hematology
Humans
Induction Chemotherapy
Infant
Infant, Newborn
irradiation-avoiding strategies
Male
Neoplasm Recurrence, Local
Oncology
Pediatrics
Prognosis
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To report the final analysis of survival outcomes for children with newly diagnosed high‐grade glioma (HGG) treated on the “Head Start” (HS) II and III protocols with chemotherapy and intent to avoid irradiation in children 6 years old or at the time of tumor progression. Results The 5‐year event‐free survival (EFS) and overall survival (OS) for all HGG patients were 25 ± 8% and 36 ± 9%, respectively. The EFS at 5 years for patients with AA and GBM were 24 ± 11% and 30 ± 16%, respectively (P = 0.65). The OS at 5 years for patients with AA and GBM was 34 ± 12% and 35 ± 16%, respectively (P = 0.83). Children 72 months old (0% and 13 ± 12%). Conclusions Irradiation‐avoiding treatment strategies should be evaluated further in young children with HGG given similar survival rates to older children receiving standard irradiation‐containing therapies.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.26118